Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Search
Sign in
Sign up
Gilead Sciences
GILD
Market cap
$147B
Overview
Fund Trends
Analyst Outlook
Journalist POV
118.30
USD
--0.18
0.15%
At close
Updated
Oct 15, 4:00 PM EDT
Pre-market
After hours
118.83
+0.53
0.45%
1D
5D
1M
3M
6M
YTD
1Y
5Y
10Y
1 day
-0.15%
5 days
-0.38%
1 month
5.12%
3 months
8.47%
6 months
11.94%
Year to date
28.75%
1 year
37.85%
5 years
87.9%
10 years
16.39%
Positive
Neutral
Negative
Sentiment
3-Months
Positive
Neutral
45.9%
Negative
Positive
Neutral
Negative
Neutral
Business Wire
17 hours ago
Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 20th European AIDS Conference (EACS) to be held in Paris, France from October 15-18. As the leader in HIV innovation, Gilead will provide an update on its strategic initiatives, key collaborations, and share new scientific data from its HIV research and development programs. The research that will be presented at EACS 2025, along with the Gilead-led symposia and supported.
Positive
Benzinga
2 days ago
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months
On Sunday, Arcus Biosciences Inc. (NYSE:RCUS) announced the first overall survival results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced, unresectable, or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.
Neutral
Business Wire
2 days ago
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will demonstrate progress in our commitment to transform how cancer is treated with new data at the European Society for Medical Oncology (ESMO) 2025 Congress October 17 – 21. Potentially Practice-Changing Results for First-Line Metastatic TNBC Treatment A late-breaking presentation (#LBA20) will feature full results from the Phase 3 ASCENT-03 study of Trodelvy® (sacituzumab govitecan-hziy) as.
Negative
Zacks Investment Research
4 days ago
3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR
Resurfaced tensions between the U.S. and China caught the market off guard in Friday's trading session, with the S&P 500 and Nasdaq falling over 2% on news that President Trump plans to impose an additional 100% tariff on Chinese goods starting November 1st.
Neutral
CNBC Television
5 days ago
Final Trades: Gilead, Rocket Lab, Palo Alto and Coinbase
The Investment Committee give you their top stocks to watch for the second half.
Neutral
Business Wire
6 days ago
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October 30, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's third quarter 2025 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for o.
Positive
Zacks Investment Research
7 days ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Positive
24/7 Wall Street
7 days ago
4 Bank of America Strong Buy Growth 10 Stocks That All Pay Dividends
BofA Securities is the investment banking and capital markets division of Bank of America, one of the largest financial institutions in the United States.
Positive
Zacks Investment Research
8 days ago
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy
Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.
Positive
Seeking Alpha
9 days ago
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Show more
See News Rankings
Sign up
Sign in
Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Theme
Close